PDCD1 and non-small cell lung carcinoma: Notably, seven randomized controlled trials had uncovered that PD-1/PD-L1 inhibitors exhibited a treatment efficacy in brain metastases of NSCLC, reducing risk of disease progression and death in NSCLC patients with brain metastases (Li et al., 2022b).